Clinical trial NCT01716637 - References

Alzheimer's Disease — Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease

Citation(s)

•   Alzheimer's Disease Education & Referral (ADEAR) Center, National Institutes of Health
  Alzheimer's Disease Fact Sheet. 2008.
•   Antony S, Kuttan R, Kuttan G
  Immunomodulatory activity of curcumin. Immunol Invest. 1999 Sep-Dec;28(5-6):291-303.
•   Becker RE
  Modifying clinical trial designs to test treatments for clinical significance in individual patients. Clin Drug Invest 2001:21:727-733.
•   Borchers AT, Sakai S, Henderson GL, Harkey MR, Keen CL, Stern JS, Terasawa K, Gershwin ME
  Shosaiko-to and other Kampo (Japanese herbal) medicines: a review of their immunomodulatory activities. J Ethnopharmacol. 2000 Nov;73(1-2):1-13. Review.
•   Calder PC
  Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):327-35. Epub 2007 Nov 26. Review.
•   Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ
  The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996 Jan;63(1):116-22.
•   Centers for Disease Control and Prevention website
  CDC Features: Alzheimer's Disease. http://www.cdc.gov/Features/Alzheimers/. 12-15-2008. 6-23-2009.
•   Chainani-Wu N
  Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. Review.
•   Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J
  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006 Oct;63(10):1402-8.
•   Griffin WS
  Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation. 2008 Jan 10;5:3. doi: 10.1186/1742-2094-5-3.
•   James MJ, Gibson RA, Cleland LG
  Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000 Jan;71(1 Suppl):343S-8S. Review.
•   Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB
  Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999 Sep 15;163(6):3474-83.
•   Kaur C, Ling EA
  Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem. 2008;15(29):3068-80. Review.
•   Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T
  Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006 Oct;56(2):159-64. Epub 2006 Aug 14.
•   Laws SM, Perneczky R, Wagenpfeil S, Müller U, Förstl H, Martins RN, Kurz A, Riemenschneider M
  TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat. 2005 Jul;26(1):29-35.
•   Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM
  The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001 Nov 1;21(21):8370-7.
•   Lo CJ, Chiu KC, Fu M, Lo R, Helton S
  Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res. 1999 Apr;82(2):216-21.
•   Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG
  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005 Oct;115(10):2774-83.
•   McGeer PL, McGeer EG
  Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol. 2002 Dec;8(6):529-38. Review.
•   Mrak RE, Griffin WS
  Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005 Mar;26(3):349-54. Review.
•   Mrak RE, Griffin WS
  Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):903-8. Review.
•   Pendurthi UR, Williams JT, Rao LV
  Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3406-13.
•   Rezai-Zadeh K, Douglas Shytle R, Bai Y, Tian J, Hou H, Mori T, Zeng J, Obregon D, Town T, Tan J
  Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J Cell Mol Med. 2009 Mar;13(3):574-88. doi: 10.1111/j.1582-4934.2008.00344.x. Epub 2008 Apr 9. Erratum in: J Cell Mol Med. 2009 May;13(5):1001.
•   Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A
  Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980 May;7(5):486-8.
•   Tarkowski E, Andreasen N, Tarkowski A, Blennow K
  Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5.
•   Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K
  Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull. 2003 Aug 15;61(3):255-60. Review.
•   Tobinick E, Gross H, Weinberger A, Cohen H
  TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 2006 Apr 26;8(2):25.
•   Tobinick E
  Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today. 2009 Feb;14(3-4):168-77. doi: 10.1016/j.drudis.2008.10.005. Epub 2008 Dec 6. Review.
•   Tobinick E
  Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res. 2007 Dec;4(5):550-2. Review.
•   Tobinick E
  Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med. 2008 Jun 10;10(6):135.
•   Tobinick EL, Gross H
  Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol. 2008 Jul 21;8:27. doi: 10.1186/1471-2377-8-27.
•   Tobinick EL
  A critique of intradiscal administration for treatment of radiculopathy. Anesthesiology. 2008 Feb;108(2):334; author reply 335. doi: 10.1097/01.anes.0000300072.56020.10.
•   Ueda H, Yamazaki C, Yamazaki M
  Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull. 2002 Sep;25(9):1197-202.
•   Venkatraman JT, Chu WC
  Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr. 1999 Dec;18(6):602-13.
•   Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C
  Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther. 2001 Jan;296(1):181-7.
•   Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM
  Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005 Feb 18;280(7):5892-901. Epub 2004 Dec 7.
•   Yano M, Kishida E, Iwasaki M, Kojo S, Masuzawa Y
  Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor. J Nutr. 2000 May;130(5):1095-101.

Open Label,Crossover,Pilot Study to Assess the Efficacy & Safety of Perispinal Admin.of Etanercept(Enbrel®) in Comb.w/Nutritional Supplements vs. Nutritional Supplements Alone in Subj. w/Mild to Mod. Alzheimer's Disease Receiving Std. Care.

Details for clinical trial NCT01716637